MLTX
MoonLake files FDA BLA for sonelokimab in hidradenitis
MoonLake submitted a BLA for sonelokimab to treat hidradenitis suppurativa, while reporting positive Phase 3 PsA results late in the quarter.
MLTX news
Latest 4 stories · newest Nov 4, 2026
MLTX
MoonLake's sonelokimab met all key PsA endpoints in Phase 3 trial.
MoonLake Immunotherapeutics reported positive results from its Phase 3 IZAR-1 trial for sonelokimab in psoriatic arthritis, alongside cash runway projections to mid-2028, reflecting potential for a leading treatment in another multi-billion dollar market.
MLTX
ML-007C-MA Phase 2 trial results released
MapLight Therapeutics reported topline data from its Phase 2 ZEPHYR trial evaluating its schizophrenia candidate ML-007C-MA. The data release is critical for the company's clinical development plans and potential market position in the psychiatric disorders treatment space.
MLTX
MoonLake Reports Strong Week 52 Sonelokimab Results in Phase 3 HS Trials
MoonLake's sonelokimab achieved 67% HiSCR75 response rate and 26% inflammatory remission at Week 52 in hidradenitis suppurativa trials, with BLA submission expected September 2026. The results position the drug as potentially best-in-class compared to competing agents, supporting advancement toward …
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same MLTX feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/MLTX/newsSTART FREE